Loading... (0%)
About liver disease

Analyst Coverage

The analysts below follow GENFIT. The opinions, projections or forecasts made by the financial analysts regarding the performance of GENFIT are the sole responsability of their authors and do not represent the opinions, projections or forecasts of GENFIT or its management. Furthermore, GENFIT provides no assurance with regard to the accuracy or correctness of such information. GENFIT has no control over the content, quality, nature or reliability of any such analyst reports, and shall have no liability whatsoever in respect of the information provided. The information provided below is for information purposes only and is not intended to imply any endorsement of GENFIT or to provide any investment advice. This list does not purport to be complete, correct or representative as of any point in time.

ANALYST

RATING

Ed Arce
H.C. WAINWRIGHT & CO.

March 12, 2018
Buy
Target Price: €105

Christophe Dombu
PORTZAMPARC

January 23, 2018
Buy (opinion unchanged)
Target Price: €69,7

Yasmeen Rahimi
ROTH CAPITAL PARTNERS

December 21, 2017
Buy
Target Price: €116

Jean-Jacques Le Fur
NATIXIS

April 26, 2017
Buy
Target Price: €45

Sébastien Malafosse
ODDO

March 3, 2017
Buy (opinion unchanged)
Target Price: €46

Arsene Guekam
KEPLER CHEUVREUX

March 3, 2017
Buy (opinion unchanged)
Target Price: €48

Fanny Meindre
CM-CIC Securities

November 3, 2016
Target Price: €62

Suzanne van Voorthuizen
KEMPEN & CO

October 11, 2016
Buy (opinion unchanged)
Target Price: €64

 
510c6a8645f4a61057f54e6b842e5bd1ZZZZZZZZZZZZZZZZZZZZZZZZZ